Cytokine Release Syndrome

Infections are the primary cause of nonrelapse mortality among individuals who undergo chimeric antigen receptor T-cell therapy, according to study results.

A novel immunotherapy approach for solid, epithelial cancers reduced tumor burden among multiple patients with metastatic colon cancer, according to phase 2 study results.

An FDA mandate that requires patients who receive chimeric antigen receptor T-cell therapy to stay within a certain radius of their treatment facility for nearly a month for adverse event monitoring may be overly restrictive.

The FDA granted accelerated approval to epcoritamab-bysp for the treatment of adults with relapsed or refractory follicular lymphoma who have received two or more previous lines of therapy.

Jae Park, MD, compared the moment to a baby being born.

CHICAGO — Treatment of with an investigational chimeric antigen receptor T-cell therapy showed an acceptable safety profile and produced durable remissions among certain patients with non-Hodgin lymphoma.

The next evolution of gene therapies may involve pitting T cells with different modifications against one another in a “race” inside a human to determine which edits produce the best results against a tumor, an expert panel predicted.

Sumanta K. Pal, MD, FASCO, expressed a mix of emotions.

Two blood biomarkers — pre-lymphodepletion C-reactive protein and ferritin — may help predict which patients with lymphoma are at risk for poor outcomes after chimeric antigen receptor T-cell therapy.

Results of a phase 1 trial for chimeric antigen receptor T cells targeting an orphan receptor in patients with relapsed or refractory multiple myeloma “thrilled” researchers, based on data presented at ASH Annual Meeting and Exhibition.